Abu-Raghif AR, et al. Effects of aqueous thyme extract against cisplatin induced nephrotoxicity in rabbits. Int J Pharm Sci Rev Res. 2015;30(1):190–4.

Google Scholar 

Abu-Raghif AR, et al. Hepatoprotective effects of thyme extract in Cisplatin-induced liver toxicity in rabbits. Der Pharmacia Lettre. 2016;8(18):22–6.

CAS  Google Scholar 

Adeleke S, et al. Microsatellite instability testing in colorectal patients with lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Personalized Med. 2022;19(4):277–86. https://doi.org/10.2217/pme-2021-0128.

Article  CAS  Google Scholar 

Amaro-Álvarez L, Cordero-Ramos J, Calleja-Hernández MÁ. Exploring the impact of pharmacogenetics on personalized medicine: a systematic review, Farmacia Hospitalaria [Preprint]. 2024. https://doi.org/10.1016/j.farma.2023.12.004

Attarbashee RK, et al. The possible effect of bosentan on the methotrexate-induced salivary gland changes in male rats: histological and immunohistochemical study. Toxicol Res. 2024;14(1):tff007. https://doi.org/10.1093/toxres/tfaf007.

Article  Google Scholar 

Avram CM, et al. The cost-effectiveness of genotyping versus sequencing for prenatal cystic fibrosis carrier screening. Prenatal Diag. 2021;41(11):1449–59. https://doi.org/10.1002/pd.6027.

Article  PubMed  Google Scholar 

Bakir WA, et al. Cytotoxicity–associated gene (CagA) producing Helicobacter pylori increased risk of developing colorectal carcinoma in Iraqi patients. Al Mustansiriyah J Pharm Sci. 2014;14(1):143–9. https://doi.org/10.32947/ajps.v14i1.139.

Article  Google Scholar 

Bartolini D, et al. Subcellular distribution and Nrf2/Keap1-interacting properties of glutathione S-transferase P in hepatocellular carcinoma. Arch Biochem Biophys. 2024;757:110043. https://doi.org/10.1016/j.abb.2024.110043.

Article  CAS  PubMed  Google Scholar 

Boussios S, et al. The developing story of predictive biomarkers in colorectal cancer. J Personalized Med. 2019;9(1):12. https://doi.org/10.3390/jpm9010012.

Article  Google Scholar 

Oliveira, ALC de SL, et al. Effect of oxaliplatin-loaded poly (d,l-lactide-co-glycolic acid) (PLGA) nanoparticles combined with retinoic acid and cholesterol on apoptosis, drug resistance, and metastasis factors of colorectal cancer. Pharmaceutics. 2020;12(2), 193. https://doi.org/10.3390/pharmaceutics12020193.

Calls A, et al. A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice. Ann Clin Transl Neurol. 2022;9(12):1985–98. https://doi.org/10.1002/acn3.51691.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y-C, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 2010;101(2):530–5. https://doi.org/10.1111/j.1349-7006.2009.01418.x.

Article  CAS  PubMed  Google Scholar 

Cheng F, et al.Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies. Front Pharmacol 14. 2023. https://doi.org/10.3389/fphar.2023.1231401.

Dreussi E, et al. Pharmacogenetics biomarkers and their specific role in neoadjuvant chemoradiotherapy treatments: an exploratory study on rectal cancer patients. Int J Mol Sci. 2016;17(9):1482. https://doi.org/10.3390/ijms17091482.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fulton MD, Najahi-Missaoui W. Liposomes in cancer therapy: how did we start and where are we now. Int J Mol Sci. 2023;24(7):6615. https://doi.org/10.3390/ijms24076615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gajewska B, et al. GSTP1 Polymorphisms and their association with glutathione transferase and peroxidase activities in patients with motor neuron disease. CNS & Neurol Disorders - Drug Targets. 2015;14(10):1328–33. https://doi.org/10.2174/1871527314666150821104019.

Article  CAS  Google Scholar 

Galante JR, et al. Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology. CNS Oncol. 2017;6(3):195–201. https://doi.org/10.2217/cns-2016-0040.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gamelin L, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359–68. https://doi.org/10.1158/1078-0432.CCR-07-0660.

Article  CAS  PubMed  Google Scholar 

Giannini V, et al. Delta-radiomics predicts response to first-line oxaliplatin-based chemotherapy in colorectal cancer patients with liver metastases. Cancers. 2022;14(1):241. https://doi.org/10.3390/cancers14010241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goekkurt E, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2009;27(17):2863–73. https://doi.org/10.1200/JCO.2008.19.1718.

Article  CAS  PubMed  Google Scholar 

Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(SUPPL. 1):S38–46. https://doi.org/10.3816/CCC.2005.s.006.

Article  CAS  PubMed  Google Scholar 

Grothey A, et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol. 2005;23(16_supple):3509–3509. https://doi.org/10.1200/jco.2005.23.16_suppl.3509.

Article  Google Scholar 

van Haren F, et al. Intravenous lidocaine affects oxaliplatin pharmacokinetics in simultaneous infusion. J Oncol Pharm Pract. 2020;26(8):1850–6. https://doi.org/10.1177/1078155220905011.

Article  CAS  PubMed  Google Scholar 

Holliday JA, Hallerman EM, Haak DC. Genotyping and sequencing technologies in population genetics and genomics. In. 2018. 83–125. https://doi.org/10.1007/13836_2017_5.

Hong J, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol. 2011;67(6):1323–31. https://doi.org/10.1007/s00280-010-1425-7.

Article  CAS  PubMed  Google Scholar 

Inada M, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther. 2010;48(11):729–34. https://doi.org/10.5414/CPP48729.

Article  CAS  PubMed  Google Scholar 

Jun L, Haiping Z, Beibei Y. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients, Swiss Medical Weekly [Preprint]. 2009. https://doi.org/10.4414/smw.2009.12754.

Kanai M, et al. Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 2010;34(2):189–93. https://doi.org/10.1016/j.canep.2010.02.008.

Article  CAS  PubMed  Google Scholar 

Katayanagi S. GSTP1 as a potential predictive factor for adverse events associated with platinum‑based antitumor agent‑induced peripheral neuropathy, Oncology Letters [Preprint]. 2019. https://doi.org/10.3892/ol.2019.9907.

Khaleel BJ, et al. Anti-angiogenic and anti-oxidant effects of 2-NTI indole derivative vs. suramin in ex vivo, in vivo, and in vitro studies. Cytotechnology. 2025;77(1):38. https://doi.org/10.1007/s10616-024-00701-7.

Article  CAS  PubMed  Google Scholar 

Khaleel BJ, et al. Inhibitory effects of carbohydrazide indole derivative on micro-blood vessel growth using ex vivo, in vivo, and in vitro assays. In Vitro Cellular & Developmental Biology – Animal. 2025;61. https://doi.org/10.1007/s11626-025-01019-0.

Kitade H, et al. Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: association between neurotoxicity and the GSTP1 polymorphism. Oncol Lett. 2014;7(5):1499–502. https://doi.org/10.3892/ol.2014.1890.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kweekel DM, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. European J Cancer. 2009;45(4):572–8. https://doi.org/10.1016/j.ejca.2008.10.015.

Article  CAS  Google Scholar 

Lecomte T, et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006;12(10):3050–6. https://doi.org/10.1158/1078-0432.CCR-05-2076.

Article  CAS  PubMed  Google Scholar 

Li H-Y, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. Asian Pac J Cancer Prev. 2012;13(7):3465–9. https://doi.org/10.7314/APJCP.2012.13.7.3465.

Article  PubMed